A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.

A study published in the Journal of Cannabis Research assessed the safety and tolerability of cannabidiol (CBD) and alcohol ...

Two tocilizumab biosimilars had similar safety, tolerability, and immunogenicity compared with the reference biologic, according to abstracts presented at the American College of Rheumatology (ACR) ...

Misako Nagasaka, MD, PhD, describes the tolerability results with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer from ...

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study It will be important to confirm this ...

Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events ...

Reasons for unmet care needs in older adults with cancer: Analyses from the 2015–2019 National Health and Aging Trends Study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...